Related references
Note: Only part of the references are listed.
Letter
Infectious Diseases
Ryuta Uraki et al.
LANCET INFECTIOUS DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Qian Wang et al.
Summary: The BQ and XBB subvariants of SARS-CoV-2 Omicron, with additional spike mutations, are rapidly expanding and have altered antibody evasion properties. Neutralization of BQ.1, BQ.1.1, XBB, and XBB.1 by vaccinated individuals and infected persons' sera was significantly impaired, including those boosted with a WA1/BA.5 bivalent mRNA vaccine. The titers against BQ and XBB subvariants were much lower than observed before, indicating that these subvariants pose a serious threat to current COVID-19 vaccines and render all authorized antibodies inactive.
Article
Microbiology
Panke Qu et al.
Summary: The emergence of new Omicron subvariants, including BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2, has shown enhanced neutralization resistance against sera from vaccinated healthcare workers and COVID-19 patients. The mutations N460K, K444T, and F486S play a significant role in driving the increased neutralization resistance of these subvariants. These findings provide insights into the evolution of SARS-CoV-2 Omicron subvariants.
CELL HOST & MICROBE
(2023)
Article
Biochemical Research Methods
Chaoran Chen et al.
Summary: The CoV-Spectrum website provides support for identifying and tracking new SARS-CoV-2 variants, with flexible mutation search capabilities and analysis on various data sources to understand characteristics and transmission of different variants.
Article
Multidisciplinary Sciences
Huiping Shuai et al.
Summary: The Omicron variant of SARS-CoV-2 shows reduced replication ability in human cells and attenuated pathogenicity in mice compared with the wild-type strain and other variants. It has lower efficiency in using TMPRSS2 and causes the lowest reduction in body weight and mortality rate among the tested strains.
Article
Multidisciplinary Sciences
Rigel Suzuki et al.
Summary: The Omicron variant of SARS-CoV-2 has spread rapidly in several countries and has shown lower fusogenicity and attenuated pathogenicity compared to the Delta variant.
Article
Microbiology
John P. Evans et al.
Summary: Recent reports show that SARS-CoV-2 Omicron variant sub-lineages BA.1, BA.1.1, and BA.2 have raised concerns about their ability to escape vaccine-induced and infection-induced immunity. A study finds that all Omicron sub-lineages, especially BA.1 and BA.1.1, exhibit significant immune escape, but this can be largely overcome by mRNA vaccine booster doses. The findings highlight the importance of booster vaccine doses for protection against all Omicron variants and provide insights into the immunity from natural infection against Omicron sub-lineages.
CELL HOST & MICROBE
(2022)
Letter
Medicine, General & Internal
Panke Qu et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Shuofeng Yuan et al.
Summary: The Omicron variant of the SARS-CoV-2 virus shows lower pathogenicity and transmissibility compared to the Delta variant in a Syrian hamster model of COVID-19. Both variants can be highly transmitted through contact transmission, and Omicron may have similar or higher transmissibility than Delta in noncontact transmission. However, Delta outcompetes Omicron in the presence of neutralizing antibodies.
Article
Microbiology
Panke Qu et al.
Summary: The newly emerged BA.2.75 variant of SARS-CoV-2 has 9 additional mutations in its spike protein compared to the ancestral BA.2 variant. It shows enhanced resistance to neutralizing antibodies, primarily due to the G446S and N460K mutations. Additionally, BA.2.75 exhibits enhanced cell-cell fusion, driven mainly by the N460K mutation.
CELL HOST & MICROBE
(2022)
Article
Medicine, Research & Experimental
Cong Zeng et al.
Article
Microbiology
Dmitriy Mazurov et al.
Article
Biotechnology & Applied Microbiology
Aaron R. Goerke et al.
METABOLIC ENGINEERING
(2008)
